- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 13.10. | AstraZeneca announces agreement with US government to reduce medicine costs | ||
| 13.10. | Positioning with purpose | ||
| 10.10. | Lilly's Omvoh shows improved outcomes in ulcerative colitis | ||
| 10.10. | Ireland's largest cancer research initiative launches second phase | ||
| 10.10. | Epsilogen appoints Cristina Oliva as chief medical officer | ||
| 10.10. | Setting the direction - how exemplary brand teams brief their agency partners | ||
| 09.10. | MHRA and FDA expand collaboration on AI and medtech regulation | ||
| 09.10. | Lilly appoints former US FDA director Peter Marks to lead infectious disease division | ||
| 09.10. | Speak up to step forward | ||
| 08.10. | Pfizer's Lorviqua recommended by NICE for lung cancer | ||
| 08.10. | Prime welcomes James Karcher to senior leadership team | ||
| 08.10. | Driving launch excellence with agile transformation | ||
| 07.10. | Havas Life London appoints Fran Griffin as Head of Strategy | ||
| 07.10. | New study highlights global overuse of antibiotics for diverticulitis | ||
| 07.10. | The Rashomon Effect | ||
| 06.10. | PMLiVE's T40 - now open for submissions! | ||
| 06.10. | Roche's small cell lung cancer therapy approved by FDA | ||
| 06.10. | Indegene acquires BioPharm to advance AI-driven life sciences marketing | ||
| 06.10. | The impact of US tariffs on healthcare and life sciences multinationals | ||
| 03.10. | Eli Lilly's Inluriyo approved by FDA for breast cancer | ||
| 03.10. | FDA accepts supplemental New Drug Application for Pharming's paediatric immunodeficiency therapy | ||
| 03.10. | Porterhouse appoints Jennifer Stewart as Medical Director in US | ||
| 03.10. | What does it mean to improve outcomes for patients with chronic conditions? | ||
| 02.10. | BMS, Takeda and Astex join AI training consortium | ||
| 02.10. | J&J's Tremfya approved by FDA for children with plaque psoriasis and psoriatic arthritis |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .